You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Bexsero

Product menu

Useful resources

GSK is proud to offer healthcare professionals additional support and resources regarding the use of ZEJULA in 1L maintenance.

Explore available content designed to support you, your clinic and your patients, using the buttons below.

Available resources

stylised graphc (tba)

Expert Perspectives

Listen to experts as they discuss their experiences

WATCH HERE
ZEJULA eDA (tba)

ZEJULA tablet formulation

ZEJULA is now available in a tablet formulation. Find out all you need to know about switching your patients to ZEJULA tablets

CLICK HERE
ZEJULA patient starter kit (tba)

Patient support

At GSK, we are fully committed to supporting you with every patient as they start their journey with ZEJULA. Check out our available resources

EXPLORE MORE

All imagery shown depicts hypothetical patients only.

Zejula Safety Information1:

Contraindications:
Hypersensitivity to the active substances or to any of the excipients.

Special warnings and precautions:
Haematologic adverse reactions (thrombocytopenia, anaemia, neutropenia) have been reported. Discontinue if a patient develops severe persistent haematologic toxicity including pancytopenia that does not resolve within 28 days following interruption.
Use with caution in patients on anticoagulants and medicinal products known to reduce the thrombocyte count hypertension, hepatic impairment.

Pregnancy/contraception:
Should not be used during pregnancy or in women of childbearing potential.

Adverse Events:
Very common: Urinary Tract Infections, thrombocytopenia, anaemia, neutropenia, leukopenia, decreased appetite, insomnia.

Please refer to the local prescribing information for a more detailed safety information.

Abbreviations

1L, first-line; FIGO, International Federation of Gynecology and Obstetrics.

References

  1. ZEJULA (niraparib) Prescribing information

For more information, please refer to the prescribing information or contact GlaxoSmithKline via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via
gulf.safety@gsk.com
To report quality complaint/s associated with the use of GSK product/s, please contact us via
 Gulf.ProductQualityComplaints@gsk.com

Department of Pharmacovigilance & Drug Information
Directorate General of Pharmaceutical Affairs & Drug Control
Ministry of Health, Sultanate of Oman
Phone Nos. 0096822357687 / 0096822357686
Fax: 0096822358489
Email: pharma-vigil@moh.gov.om
Website: www.moh.gov.om

 دائرة التيقظ و المعلومات الدوائية
المديرية العامة للصيدلة و الرقابة الدوائية
وزارة الصحة, سلطنة عمان
0096822357687 / 0096822357686 :هاتف
0096822358489 :فاكس
pharma-vigil@moh.gov.om :البريد الالكتروني
www.moh.gov.om :الموقع الالكتروني

Trademarks are owned by or licensed to the GSK group of companies.
©2024 GSK group of companies or its licensor. All rights reserved. 

PM-RCH-NRP-SRCH-240001 | April 2024